Logo image of SURG

SURGEPAYS INC (SURG) Stock Fundamental Analysis

NASDAQ:SURG - Nasdaq - US86882L2043 - Common Stock - Currency: USD

2.7  +0.04 (+1.5%)

After market: 2.71 +0.01 (+0.37%)

Fundamental Rating

3

SURG gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 21 industry peers in the Wireless Telecommunication Services industry. Both the profitability and financial health of SURG have multiple concerns. SURG has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SURG had negative earnings in the past year.
SURG had a negative operating cash flow in the past year.
In the past 5 years SURG reported 4 times negative net income.
In multiple years SURG reported negative operating cash flow during the last 5 years.
SURG Yearly Net Income VS EBIT VS OCF VS FCFSURG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

1.2 Ratios

SURG has a Return On Assets of -348.50%. This is amonst the worse of the industry: SURG underperforms 95.24% of its industry peers.
SURG has a worse Return On Equity (-696.64%) than 90.48% of its industry peers.
Industry RankSector Rank
ROA -348.5%
ROE -696.64%
ROIC N/A
ROA(3y)-47.87%
ROA(5y)-71.76%
ROE(3y)-79.87%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SURG Yearly ROA, ROE, ROICSURG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SURG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SURG Yearly Profit, Operating, Gross MarginsSURG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

More info and screens

3

2. Health

2.1 Basic Checks

SURG does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SURG has been increased compared to 1 year ago.
SURG has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, SURG has a worse debt to assets ratio.
SURG Yearly Shares OutstandingSURG Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
SURG Yearly Total Debt VS Total AssetsSURG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

SURG has an Altman-Z score of -9.80. This is a bad value and indicates that SURG is not financially healthy and even has some risk of bankruptcy.
SURG has a worse Altman-Z score (-9.80) than 90.48% of its industry peers.
A Debt/Equity ratio of 0.24 indicates that SURG is not too dependend on debt financing.
With an excellent Debt to Equity ratio value of 0.24, SURG belongs to the best of the industry, outperforming 90.48% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF N/A
Altman-Z -9.8
ROIC/WACCN/A
WACC8.98%
SURG Yearly LT Debt VS Equity VS FCFSURG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

SURG has a Current Ratio of 1.72. This is a normal value and indicates that SURG is financially healthy and should not expect problems in meeting its short term obligations.
SURG has a Current ratio of 1.72. This is amongst the best in the industry. SURG outperforms 85.71% of its industry peers.
A Quick Ratio of 1.41 indicates that SURG should not have too much problems paying its short term obligations.
SURG has a Quick ratio of 1.41. This is in the better half of the industry: SURG outperforms 66.67% of its industry peers.
Industry RankSector Rank
Current Ratio 1.72
Quick Ratio 1.41
SURG Yearly Current Assets VS Current LiabilitesSURG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

5

3. Growth

3.1 Past

SURG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -342.61%.
SURG shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -70.08%.
The Revenue has been growing by 18.83% on average over the past years. This is quite good.
EPS 1Y (TTM)-342.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-642.86%
Revenue 1Y (TTM)-70.08%
Revenue growth 3Y6.01%
Revenue growth 5Y18.83%
Sales Q2Q%-66.35%

3.2 Future

SURG is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 49.15% yearly.
SURG is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 83.41% yearly.
EPS Next Y96.29%
EPS Next 2Y49.15%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year125.45%
Revenue Next 2Y83.41%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SURG Yearly Revenue VS EstimatesSURG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M 150M 200M
SURG Yearly EPS VS EstimatesSURG Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 0 1 -1 -2

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

SURG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 5.14, the valuation of SURG can be described as very cheap.
95.24% of the companies in the same industry are more expensive than SURG, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 22.39. SURG is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 5.14
SURG Price Earnings VS Forward Price EarningsSURG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SURG Per share dataSURG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

SURG's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
SURG's earnings are expected to grow with 49.15% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y49.15%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SURG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SURGEPAYS INC

NASDAQ:SURG (6/12/2025, 8:00:01 PM)

After market: 2.71 +0.01 (+0.37%)

2.7

+0.04 (+1.5%)

Chartmill FA Rating
GICS SectorCommunication Services
GICS IndustryGroupTelecommunication Services
GICS IndustryWireless Telecommunication Services
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-11 2025-08-11/amc
Inst Owners10.05%
Inst Owner Change-2.26%
Ins Owners31.04%
Ins Owner Change1.99%
Market Cap55.11M
Analysts80
Price Target8.93 (230.74%)
Short Float %3.18%
Short Ratio0.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-182.14%
Min EPS beat(2)-304.04%
Max EPS beat(2)-60.24%
EPS beat(4)0
Avg EPS beat(4)-339.26%
Min EPS beat(4)-824.37%
Max EPS beat(4)-60.24%
EPS beat(8)2
Avg EPS beat(8)-155.49%
EPS beat(12)4
Avg EPS beat(12)-62.05%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.22%
Min Revenue beat(2)-14.86%
Max Revenue beat(2)14.43%
Revenue beat(4)1
Avg Revenue beat(4)-12.18%
Min Revenue beat(4)-45.89%
Max Revenue beat(4)14.43%
Revenue beat(8)2
Avg Revenue beat(8)-8.53%
Revenue beat(12)4
Avg Revenue beat(12)-6.55%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)29.63%
PT rev (3m)52.17%
EPS NQ rev (1m)-200%
EPS NQ rev (3m)-278.95%
EPS NY rev (1m)-30.77%
EPS NY rev (3m)47.69%
Revenue NQ rev (1m)-1.86%
Revenue NQ rev (3m)-3.89%
Revenue NY rev (1m)10.36%
Revenue NY rev (3m)41.18%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 5.14
P/S 1.38
P/FCF N/A
P/OCF N/A
P/B 7.03
P/tB 17.08
EV/EBITDA N/A
EPS(TTM)-2.79
EYN/A
EPS(NY)0.53
Fwd EY19.46%
FCF(TTM)-1.61
FCFYN/A
OCF(TTM)-1.58
OCFYN/A
SpS1.96
BVpS0.38
TBVpS0.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -348.5%
ROE -696.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-47.87%
ROA(5y)-71.76%
ROE(3y)-79.87%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover2.56
Health
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.72
Quick Ratio 1.41
Altman-Z -9.8
F-Score2
WACC8.98%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-342.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-642.86%
EPS Next Y96.29%
EPS Next 2Y49.15%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-70.08%
Revenue growth 3Y6.01%
Revenue growth 5Y18.83%
Sales Q2Q%-66.35%
Revenue Next Year125.45%
Revenue Next 2Y83.41%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-421.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year95.05%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-591.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-562.95%
OCF growth 3YN/A
OCF growth 5YN/A